A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors

NCT05025085 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: AGEN1777
DRUG: a PD-1 inhibitor

Sponsor

Agenus Inc.